CARGO Therapeutics, formerly Syncopation Life Sciences, is advancing a new generation of adoptive cell therapies for cancers. Our cell therapies focus on addressing the primary mechanisms of failure, or resistance and relapse, to the currently available Chimeric Antigen Receptor T-cell (CAR T) therapies. Despite the advances made by existing autologous CAR T therapies, these treatments are only curative for less than half of all cancer patients, and therapeutic failure, resistance, and relapse are common. In addition, far too many patients are unable to access these potentially curative therapies due to barriers, including manufacturing, supply, time, and reimbursement challenges. CARGO is actively working to address these barriers with novel solutions that address the problems of resistance and access. Through smarter science, CARGO is developing and delivering CAR T-cell therapies to cure more patients. Focused on the delivery of complex therapeutic cargo, we enable the multiplex engineering necessary to overcome multiple mechanisms of tumor resistance, to counter inhibition by solid tumors, and in the allogeneic setting to evade immune rejection. From research to manufacturing to clinical care, we at CARGO aspire to disrupt the status quo to overcome resistance and maximize access to curative therapeutics.